title: [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
abstract: Androgenetic alopecia in men is genetically determined, but occurs only when the testosterone metabolite dihydrotestosterone (DHT) is present in normal levels. The drug, finasteride, inhibits the enzyme 5-alpha-reductase II, which is responsible for converting testosterone to DHT. One 1 mg tablet (Propecia) of finasteride daily lowers serum DHT levels by about 70%, and increases serum testosterone by 10%. The efficacy of finasteride 1 mg has been demonstrated in a randomized, double-blind, placebo-controlled clinical trial involving more than 1,500 men in whom a significant increase in hair density over a specified area of the scalp, and a significant improvement in appearance was noted. Following one year to treatment 48%, and following 2 years 66%, of the finasteride patients (placebo group 7% after both treatment periods) presented with visibly thicker hair growth. Side effects such as decreased libido, ejaculation disorders and erectile dysfunction were seen in fewer than 2% of the men in both the finasteride and placebo groups.
authors.affiliation: Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, München. hans.wolff@lrz.uni-muenchen.de
authors.forename: H
authors.initials: H
authors.lastname: Wolff
authors.forename: C
authors.initials: C
authors.lastname: Kunte
mesh_terms: D000505:Alopecia / Q000188:drug therapy* / Q000209:etiology; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride